In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.

Table of ContentsSection 1 General Strategies for Molecular Targeting in OncologyChapter 1 The Cell Cycle: Therapeutic Targeting of Cell CycleRegulatory Components and Effector Pathways in CancerChad D. Knights and Richard G. PestellChapter 2 mTOR: Properties and TherapeuticsJohn B. Easton and Peter J. HoughtonChapter 3 Ras/Raf/MEK InhibitorsJoseph A. SparanoChapter 4 17AAG: Targeting the Molecular Chaperone Heat Shock Protein 90Len Neckers and Percy IvyChapter 5 The Cancer Epigenome: Can it be targeted for therapy?Sam Thiagalingam and Douglas V. FallerSection 2 Molecular Targeting for Specific Disease SitesChapter 6 Molecular targeting in upper gastrointestinal malignanciesScott WadlerChapter 7 Molecular Targeting of Colorectal Cancer: An Idea Whose TimeHas ComeMark L. Sundermeyer, Alfonso Bellacosa, and Neal J. MeropolChapter 8 Molecular Targeting in Hepatocellular CarcinomaJonathan D. Schwartz. and Josep M. LlovetChapter 9 Molecularly Targeted Therapy in Pancreatic CancerAnupama Goel and Peter KozuchChapter 10 Untargeted Use of Targeted Therapy: A Dilemma in Non-SmallCell Lung CancerCheryl Ho, Angela M. Davies, Primo N. Lara, O. Gautschi, P.C. MackPaul H. Gumerlock and David R. GandaraChapter 11 Molecular Targeting in Oncology: Renal Cell CancerOlwen Hahn and Walter StadlerChapter 12 Targeted Therapies for Prostate CancerElisabeth I. Heath and Michael A. CarducciChapter 13 Molecular Targets in Ovarian Cancer and Endometrial CancerNilofer S. Azad, Gisele Sarosy, and Elise C. KohnChapter 14 Targeted Therapy for Breast CancerDeena M. Atieh and Linda T. VahdatChapter 15 MelanomaAkshay Gupta and John M. KirkwoodSection 3 Classes of Drugs for Molecular Targeting in OncologyChapter 16 Antibody Therapy of CancerHossein Borghaei, Liat Binyamin, Igor Astsaturov, and Louis M. WeinerChapter 17 Nucleic Acid Therapies for Cancer TreatmentDan T. Vogl and Alan M. GewirtzChapter 18 Engineering Oncolytic Measles Viruses for Targeted CancerTherapyTakafumi Nakamura and Stephen J. RussellChapter 19 Vaccines as Targeted Cancer TherapyMiguel-Angel Perales, Jedd D. Wolchok and Howard L. KaufmanChapter 20 Cytokine based therapy for cancerHenry B. Koon and Michael B. AtkinsChapter 21 Cyclooxygenase-2 (Cox-2) as a Target for Cancer Preventionand TreatmentMonica Bertagnolli, Jaye L. Viner, and Ernest T. HawkSection 4 Specific Drugs for Molecular Targeting in OncologyChapter 22 Imatinib Mesylate (Gleevec) and the emergence ofchemotherapeutic drug-resistant mutationGerald V. DenisChapter 23 Development of a Targeted Treatment for Cancer: The Exampleof C225 (Cetuximab)John MendelsohnChapter 24 VEGF Inhibition for Cancer TherapyShermini Saini and Herbert HurwitzChapter 25 Somatostatin analogue therapyManish C. Champaneria, M.D., Irvin M. Modlin, M.D., Ph.D., D.Sc., IgorLatich, M.D., Jan Bornschein, Ignat Drozdov, Mark Kidd, Ph.D.Section 5 Challenges in Molecular Targeting in OncologyChapter 26 Patient Selection for Rational Development of NovelAnticancer AgentsGrace K. Dy and Alex A. AdjeiChapter 27 Clinical Trial Design with Targeted AgentsSarita Dubey and Joan H. SchillerChapter 28 How to define treatment success or failure if tumors don'tshrink: Consequences for trial design.JJEM Kitzen, MJA de Jonge, and J VerweijChapter 29 Molecular Imaging in OncologyLalitha Shankar, Anne Menkens, and Daniel C. SullivanChapter 30 Combinations of Molecular Targeted Therapies - Opportunitiesand ChallengesHelen X. Chen and Janet E. DanceyChapter 31 Preclinical Development of Molecularly Targeted Agents